Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Aura Biosciences' Stock Gains As FDA Grants Fast Track Status To Bladder Cancer Drug

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Aura Biosciences’ (NASDAQ:AURA) belzupacap sarotalocan (AU-011) for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

The company has planned Phase 1 clinical trial with belzupacap sarotalocan in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) will evaluate the safety and early proof of mechanism, assess distribution, local necrosis and evidence of immune activation.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.